FOLH1 and posterior cortical atrophy: Though initial attempts failed to bring the expected results thus integrating PET/CT in the diagnosis and treatment algorithms of PCa, the recent United States Food and Drug Administration (FDA) approval of fluciclovine (18F) as well as new advances such as the discovery of the Prostate-specific membrane antigen (PSMA), a well-characterized imaging biomarker, have brought this imaging modality back into the spotlight.